Akero Therapeutics Inc. (NASDAQ:AKRO) is one of the best mid cap pharma stocks to buy. On July 16, AstraZeneca announced that ...

AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain amyloidosis in two Phase III trials. A ...

AstraZeneca on Wednesday said that its experimental therapy anselamimab did not meet the main goal of a late-stage study for ...

An antibody being developed by AstraZeneca for the treatment of light chain (AL) amyloidosis has failed to move the needle in ...

Topline data were announced from a phase 3 clinical program evaluating anselamimab in patients with Mayo stages 3a and 3b light chain (AL) amyloidosis.

Hereditary amyloidosis is usually caused by inherited genetic mutations that cause abnormal amyloid proteins to build up and damage different organs in the body. Here’s what you need to know ...

PITTSBURGH (KDKA) -- Amyloidosis is a rare condition that used to almost always be fatal, but doctors are finally making progress in treating it. "I had so many symptoms, and I really didn't think ...

Dr. Jose Nativi is a cardiologist and director of the amyloidosis program at University of Utah Health Care and Huntsman Cancer Institute. He explains what amyloidosis is and why it’s so tricky to ...

AA amyloidosis is an extremely rare disease, and doctors have yet to understand exactly why it shows up in some individuals and not others. The condition is, however, known to be linked to other ...

The symptoms of amyloidosis vary widely due to the many different parts of the body that can be affected by the disease. If amyloid protein accumulates in a single part of the body, the disease is ...

Cardiac amyloidosis is not nearly as rare as one might think, and with effective treatments finally emerging in recent years, there’s a need to increase awareness of the condition to allow for earlier ...